MicroPort Orthopedics Completes Construction of Suzhou's First 100-Meter 'Sky-High Smart Factory' to Boost Global R&D and Manufacturing Capacity

Sep 20, 2024 17:36 CST Updated 17:36

MicroPort

Medical Device Manufacturing Enterprise

Instrument Family

Medical Device Media Reporting Pioneer

Share Professional Medical Device Knowledge

Source:Instrument Family,Reproduction without authorization is prohibited, and reproduction is allowed 24 hours later.

On September 19, Suzhou MicroPort Orthopedics (Group) Co., Ltd. (hereinafter referred to as "MicroPort® Orthopedics Suzhou")" The plant has successfully passed the completion planning verification, becomingSuzhou's First 100-Meter "Skyscraper Factory".

This plant is a new construction project of MicroPort® Suzhou Park, located on the northeast side of Zhongxin Avenue and the west side of Fengli Street in Suzhou Industrial Park.The total construction area of the plant is approximately 129,000 square meters, with 23 floors above ground and 3 floors underground, reaching a building height of 99.6 meters, and a total investment of about 750 million yuan.The project includes an implant production workshop, a surgical tool production workshop, an additive research and processing center, and a logistics distribution center.

It is reported that Suzhou is one of the most important pieces in MicroPort's global orthopedics map.MicroPort® Suzhou Park is an orthopedic innovation industrial park developed by MicroPort Orthopedics in Suzhou Industrial Park, integrating functions such as research and development, manufacturing, logistics, and academia.Covering an area of 142 mu (approximately 94,667 square meters) with a total construction area of about 170,000 square meters, it boasts a world-class hip and knee joint research and development center and training center, as well as world-leading refined and automated manufacturing capabilities.

Rendering of MicroPort® Suzhou Park

MicroPort® Orthopedics (Suzhou) is the orthopedic business unit of MicroPort Medical Group, and since its establishment, it has been driven by innovation as its core.Rapidly rising in the global orthopedic medical device industry, it has now entered the top five global orthopedic product manufacturers.

The successful completion of this skyscraper factory marks an important step for MicroPort in further deepening its global strategic layout. The new facility will significantly enhance the company's R&D and production capabilities on a global scale, through...Integrate global manufacturing resources,Greatly optimize supply chain efficiency and flexibility, laying a solid foundation for future continuous innovation and business expansion.

One of the largest orthopedic device enterprises in China

MicroPort Scientific Corporation, established in 1998, is an innovative high-end medical device group. Its business covers twelve major clusters: cardiovascular and structural heart disease, electrophysiology and heart rhythm management systems, bone and soft tissue repair technology, aortic and peripheral vascular diseases, cerebrovascular and neuromodulation sciences, surgical critical care and robotics, endocrine management and assisted reproduction, urology, gynecology, gastroenterology, respiratory diseases, ear-nose-throat, oral, ocular, and body contouring aesthetics, in-vitro diagnostics and imaging inside and outside the body, solid tumor treatment technology within the body, insomnia, depression, and rehabilitation medicine.

In 2009, MicroPort established MicroPort Scientific Corporation, officially entering the orthopedics field. In 2011, the company further expanded by acquiring 100% of the equity of Suzhou Best, gaining an advantage in the trauma and spine product lines, and rapidly expanding the market base for its orthopedic business.

In 2012, MicroPort Orthopedics Medical Technology (Suzhou) Co., Ltd. was established in Suzhou Industrial Park, dedicated to the research, development, production, and sales of products for hip and knee joints, spinal internal implants, instruments, biomaterials, sports medicine, and novel trauma products.

MicroPort® Orthopedics (Suzhou)It has now developed into the global headquarters of MicroPort's orthopedic business, with a world-class hip and knee joint research and development center and training center.Global revenue exceeded 1.6 billion yuan in 2023.

In addition to the Suzhou headquarters, the company has also established its global headquarters in Arlington, Tennessee, USA.

The Two Headquarters Have Different Focuses and Collaborate in Operations:The Suzhou headquarters is an orthopedic innovation industrial park integrating functions such as R&D, manufacturing, logistics, and academia.And the United StatesHeadquartered as a center for research and development, production, and global logistics distribution, the company boasts a team of professional management and technical talents along with advanced production and testing equipment. In the past three years, it has successfully developed multiple new orthopedic joint products, helping patients achieve faster full-function rehabilitation.

Orthopedic Giant Completes Metamorphosis

Since 2009, after more than a decade of independent research and development and efficient integration of global resources and markets, MicroPort® Orthopedics has finally completed its "metamorphosis."Revenue grew from USD 410,000 in 2013 to USD 237 million in 2023.

Financial reports show，In 2023, MicroPort's orthopedic medical device business achieved marketing revenue of $2.37 billion (approximately RMB 1.67 billion), representing a year-on-year increase of 7.3%.Meanwhile, through continuous promotion of global production cooperation and implementation of various cost-reduction and efficiency-enhancement measures, the net loss of MicroPort's global orthopedic business narrowed by 9.7% year-on-year.

Revenue in China was $27.3 million, representing a year-over-year increase of 33.8%.Joint implant volume achieves 96% growth, imported knee joint product shipments increase by 203% year-on-year, market share doubles, and competitiveness significantly strengthens.

International (non-China) business revenue reached 210 million USD, a year-on-year increase of 4.6%.(Excluding the impact of exchange rates).

Orthopedic MedicalThe device business provides comprehensive orthopedic solutions, with products covering joint reconstruction, spine, trauma, and other specialized implants and tools. Earlier this year, the zirconium-niobium alloy femoral condyle and Evolution® CCK knee revision system developed by the company both received registration certificates issued by the National Medical Products Administration (NMPA).

Zirconium Niobium Alloy Femoral Condyle

Among them,The zirconium-niobium alloy femoral condyle is the first domestically produced zirconium-niobium alloy femoral condyle in China, offering low allergenicity, high wear resistance, and high hydrophilicity.In terms of product design, the articular surface of this product continues the medial pivot knee implant design that MicroPort® Orthopedics has consistently adhered to. This zirconium-niobium alloy femoral condyle can be used in conjunction with other components of the MicroPort® Orthopedics Evolu™ knee system, further enhancing the expected lifespan of the implant while continuing to provide high-quality prostheses, thereby benefiting patients even more.

Evolution® CCK Knee Revision System

The Evolution® CCK Revision Knee System builds on the spherical geometric design of the original imported Evolution® Knee System from MicroPort® Orthopedics.Able to maintain high stability and high conformity of the prosthesis, achieve high flexion, and provide solutions for complex knee replacement and knee revision surgeries for patients.At the same time, it maintains the kinematic advantages of the medially pivoting design, reconstructing the knee joint kinetics for patients.

Orthopedic Market Sees Explosive Growth

The "2023-2028 In-depth Market Research and Investment Prospect Forecast Analysis Report on the Orthopedic Device Industry" released by the New Think Tank Industry Research Center shows that in recent years, with the continuous improvement of global orthopedic treatment capabilities and the rapid development of orthopedic device technology, the global demand for orthopedic devices has continued to rise.As of 2022, the global orthopedic device market size has surpassed the 250 billion yuan mark.

China's orthopedic medical device industry is currently in an era of market expansion and import substitution.According to data from the Southern Medical Economic Research Institute, calculated based on revenue,The market size of orthopedic implant medical devices in China grew from 16.4 billion yuan in 2015 to 42.4 billion yuan in 2021, with a compound annual growth rate of 17.15%.

The market for orthopedic implant consumables in China will still be dominated by foreign brands. Foreign products occupy a significant share in the joint and spinal categories, and multinational orthopedic device companies have a strong competitive advantage in the high-end market due to their product technical performance and quality standards.

Image Source: Sanza Venture Capital

In 2021, China further advanced the reform of centralized bulk procurement of high-value medical consumables, implementing the requirements of relevant documents for the governance of high-value medical consumables reform. This aims to further improve procurement efficiency and promote the normalization of volume-based procurement.According to incomplete statistics, between 2021 and 2022, the average price reduction for trauma, joint, and spinal products in national and provincial-level bulk procurement in China was 73-89%.

Thanks to the centralized procurement policy for orthopedic consumables and the substitution of domestically produced products, the orthopedic implant consumables industry is expected to continuously increase its market concentration. Leading companies in China are likely to further expand their market share, also driving more Chinese companies to participate in international competition.

According to customs statisticsAccording to the research and analysis of the online query platform,In 2022, the export of orthopedic implants in China continued to increase, with a total export value of approximately US$8.63 billion, representing a year-on-year growth of 21%.Among the sub-markets, the export value of trauma/spine reached approximately US$755 million, increasing by 17% year-on-year; the export value of artificial joints was about US$294 million, year-on-year...Annual growth of 35%

Against this backdrop, MicroPort Orthopedics' "Skyscraper Factory" can be said toIt comes at an opportune time. With the growing global demand for orthopedic implants, it is expected to become an important platform for MicroPort Orthopedics to expand into international markets. Medical Device News will wait and see.

END

Impact Factor 58.7! Huaxi-United Imaging Intelligence Latest Research Published in "Nature Medicine"

Chinese Endoscope Giant Acquires European Counterpart

The World's Second-Largest Ophthalmic Device Giant May Be Up for Sale

Dental Instrument Leader Completes Major Acquisition

443.1 Billion: The Largest IPO on HKEX This Year Has Arrived

10.6 Billion, Major Move by Imaging Equipment Giant

Boston Scientific: Another Major Acquisition

Imaging Unicorn, or Delisting

$3.4 Billion: Medical Device Giant Completes Acquisition

Chinese Imaging Giant to Attempt IPO for the Fifth Time

BusinessBusiness cooperation email: qxzj@landianyiliao.com